Cellosaurus cell line AB0023 (CVCL

Cellosaurus AB0023 (CVCL_C6IJ)

Cross-references
Cell line name	AB0023
Accession	CVCL_C6IJ
Resource Identification Initiative	To cite this cell line use: AB0023 (RRID:CVCL_C6IJ)
Comments	Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized simtuzumab (GS 6624) therapeutic antibody that was investigated in a failed phase 2 clinical study for the treatment of idiopathic pulmonary fibrosis. Characteristics: The monoclonal produced by this hybridoma allosterically inhibits the activity of LOXL2 (PubMed=20439985). Monoclonal antibody isotype: Not specified. Monoclonal antibody target: UniProtKB; Q9Y4K0; Human LOXL2 (Note=Also reacts with mouse).
Species of origin	Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Hierarchy	Parent: CVCL_4032 (P3X63Ag8.653)
Category	Hybridoma
Publications	PubMed=20439985; DOI=10.1074/jbc.M109.094136; PMCID=PMC2898315 Hector M. Rodriguez, Maria Vaysberg, Amanda Mikels, Scott Alan McCauley, Arleene C. Velayo, Carlos Aurelio Garcia, Victoria Smith; Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor. J. Biol. Chem. 285:20964-20974(2010) Patent=US8680246 Scott Alan McCauley, Hector M. Rodriguez, Carlos Aurelio Garcia, Victoria Smith; Antibodies that bind to lysyl oxidase-like 2 (LOXL2). Patent number US8680246, 25-Mar-2014 Patent=US10494443 Victoria Smith, Scott Ogg, Peter Van Vlasselaer, Vivian E. Barry, Derek Marshall, Alison Kay Holzer, Hector M. Rodriguez, Miho Oyasu, Scott Alan McCauley, Carlos Aurelio Garcia, Donna Hiroko, Tokuoka Biermann; LOX and LOXL2 inhibitors and uses thereof. Patent number US10494443, 03-Dec-2019
Encyclopedic resources	Wikidata; Q116048468
Entry history
Entry creation	15-Dec-2022
Last entry update	21-Mar-2023
Version number	2